(Q34444895)

2 August 2017

1 reference

title

Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease (English)

1 reference

2 August 2017

0 references

0 references

1 reference

cardiovascular disease

1 reference

Nathalie Esser

1

1 reference

2 August 2017

Nicolas Paquot

series ordinal

2

1 reference

2 August 2017

André J Scheen

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

25 October 2014

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

24

1 reference

2 August 2017

3

1 reference

2 August 2017

283-307

1 reference

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Type 2 diabetes mellitus: a metabolic autoinflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation in atherosclerosis: from pathophysiology to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Anti-inflammatory therapies for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Role of TNF-alpha in vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

TNF-alpha and insulin resistance: summary and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Infliximab and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Mechanisms of disease: inflammasome activation and the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammasome and cytokine blocking strategies in autoinflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Targeting inflammation in the treatment of type 2 diabetes: time to start

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Emerging anti-inflammatory drugs for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation and cardiovascular disease: from pathogenesis to therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

"Anti-inflammatory" drugs and their effects on type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Anti-inflammatory therapy in chronic disease: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Targeting inflammation in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Novel directions for diabetes mellitus drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation modulation and cardiovascular disease prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Low-dose colchicine for secondary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Potential role of salicylates in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

AMPK: a target for drugs and natural products with effects on both diabetes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

AMPK: mediating the metabolic effects of salicylate-based drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Salsalate improves glycemia and inflammatory parameters in obese young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The effect of salsalate therapy on endothelial function in a broad range of subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Evaluating the efficacy of Salsalate on prediabetic and diabetic patients with fatty liver: A randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The acute effects of low-dose TNF-α on glucose metabolism and β-cell function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of etanercept in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Systemic blockade of TNF-α does not improve insulin resistance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Immunological and inflammatory functions of the interleukin-1 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Physiologic versus diabetogenic effects of interleukin-1: a question of weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interleukin-1 beta: a potential link between stress and the development of visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Role of IL-1beta in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The inflammasome puts obesity in the danger zone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Administration of IL-1 trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inhibition of IL-1beta improves fatigue in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

IL-6 in diabetes and cardiovascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Targeting gp130 to prevent inflammation and promote insulin action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Adiponectin and interleukin-6 in inflammation-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

AMPK, insulin resistance, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

AMPK and vasculoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The ancient drug salicylate directly activates AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Direct AMP-activated protein kinase activators: a review of evidence from the patent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

AMPK and SIRT1: a long-standing partnership?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

SirT1 regulates adipose tissue inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Sirtuin-1 is a nutrient-dependent modulator of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Targeting sirtuins for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Sirtuins as possible drug targets in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Resveratrol levels and all-cause mortality in older community-dwelling adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Resveratrol: therapeutic potential for improving cardiometabolic health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Evidence for a common mechanism of SIRT1 regulation by allosteric activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Small-molecule allosteric activators of sirtuins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Leptin and mTOR: partners in metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Inhibition of the mTOR pathway: a possible protective role in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Everolimus, a promising medical therapy for coronary heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Molecular targets related to inflammation and insulin resistance and potential interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

Anakinra treatment in patients with gout and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.974804

10.1517/13543784.2015.974804

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference